The European Medicines Agency (EMA) could approve the Pfizer / BioNTech vaccine against COVID-19 this May for over 12 years, according to the director of the regulatory body, Emer Cooke. Although in principle the go-ahead was scheduled for the month of June, the agency is trying to advance it to the end of this month, in line with the United States and Canada, which have already given the green light for this drug to be inoculated in this strip of age.
“For now, we have set ourselves the goal of approval in June, although we are trying to speed up this process by the end of MayCooke told various European media outlets. “We were promised data from the review carried out by Canada in the next two weeks and this could speed up the review,” he explained, making it clear that, after the approval of the EMA, the beginning of the inoculation in minors will depend on each state. member of the EU.
On May 3, the EMA began evaluating the use of the Comirnaty-Pfizer / BioNTech-brand vaccine in the age group 12 to 15 years, and assured that it awaited the results of its review in June.
Approval in the United States and Canada
Last Monday, the United States Food and Drug Administration (FDA) approved the use of this vaccine in young people between 12 and 15 years old. In this country, it is already being administered to those over 16 years of age.
Canada last week became the first country in the world to authorize Pfizer’s preparation for ages 12 and over, after the pharmaceutical company announced at the end of March 100% efficiency in a study of 2,260 individuals in that age group.
–
– .
